Kalvista Pharmaceuticals Limited
- Address
- Porton Science Park, Bybrook Road, Porton Down
Sponsor Overview
Specializations
Hereditary Angioedema Therapeutics
Kalvista Pharmaceuticals Limited focuses its clinical research on Hereditary Angioedema (HAE) Type I and Type II, with studies addressing both adolescent and adult populations as well as younger children. The sponsor’s work centers on treatment options for HAE attacks and on the safety and tolerability of therapies used in this rare immunological disorder.
- HAE Type I and Type II
- Angioedema attack treatment
- Rare disease management
Clinical activity includes research across multiple countries and collaborating sites, reflecting an international focus on hereditary swelling disorders and age-specific therapeutic needs.
Pediatric Allergy and Immunology
The sponsor also supports research in pediatric HAE, with attention to children aged 2 to under 12 years. This area highlights the need for therapies suitable for early-life disease control in a rare complement-mediated condition.
- Pediatric patients
- Safety and tolerability
- Childhood angioedema
These studies extend the sponsor’s interest beyond adult care to age-appropriate treatment options for children living with recurrent swelling episodes.
Long-Term Disease Control
Kalvista’s research portfolio includes evaluation of long-term administration in HAE, with emphasis on sustained use in patients who require ongoing management of attacks. This places focus on chronic treatment considerations within rare immunology.
- Long-term safety
- Chronic attack prevention
- Ongoing HAE care
The clinical interest here lies in maintaining therapeutic use over time for patients with repeated angioedema episodes.
Oral Acute Treatment Development
The trial portfolio indicates interest in acute attack therapy for HAE, including oral treatment approaches designed for rapid use during swelling events. This area is closely tied to improving practical management of bradykinin-mediated angioedema.
- Attack treatment
- Oral therapy
- Rapid symptom control
Research in this domain supports therapeutic development aimed at addressing the immediate burden of HAE attacks in both adult and pediatric patients.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Safety, Pharmacokinetics, and Efficacy of Sebetralstat in Pediatric Patients with Hereditary Angioedema Type I or II |  France Germany Italy | Not Recruiting |
| Long-term Safety Evaluation of Sebetralstat (KVD900) for On-demand Treatment of Angioedema Attacks in Hereditary Angioedema Type I or II Patients |  Austria Bulgaria France Germany Greece Hungary Italy Poland Portugal Romania Slovakia Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 27 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases2 trials249 other sponsors
Partnered Research Centres
27 centres- Address
- 264 Boulevard de Saint Pierre, 13005 Marseille
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
- Address
- 26 Avenue Du Docteur Arnold Netter, 75012 Paris
- Address
- Dinokratous 70, 115 21 Athens
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Via Trabucco 180, 90146 Palermo
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kalvista Pharmaceuticals Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.